In addition, since several potential side effects of SGLT2 inhibitors, about which many clinicians were previously concerned, have substantially been wiped out at present, we should start SGLT2 inhibitors at an early stage of diabetes in subjects to whom therapy with SGLT2 inhibitors is thought to be appropriate in clinical practice as well. This evidence concerns the gene SLC5A2 and diabetes mellitus.